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Osteoporosis is a costly condition1,2 and is the fifth 
most common musculoskeletal problem managed in 
general practice at 0.9 per 100 patient encounters.3 
Secondary prevention of osteoporotic fracture is poorly 
implemented4 despite the availability of efficacious 
treatments. 
	
Strontium	 ranelate,	 a	 pharmacological	 treatment	 for	
osteoporosis	which	 is	 relatively	new	 to	Australia,	has	been	
available	 on	 the	 Pharmaceutical	 Benefits	 Scheme	 (PBS)	
by	 authority	 prescription	 since	April	 2007.5	 Strontium	 is	
the	pharmacologically	 active	 component	of	 the	compound	
and	 has	 been	 shown	 to	 simultaneously	 decrease	 bone	
resorption	and	stimulate	bone	formation	both	in	vitro	and	in	
animal	models,6	 although	 the	exact	mechanisms	 for	 these	
actions	are	as	yet	unclear.	
	 O’Donnell	et	al1	performed	a	systematic	review	to	assess	
the	 efficacy	 and	 adverse	 effects	 of	 strontium	 compared	
to	either	placebo	or	other	 treatments	 for	 postmenopausal	
osteoporosis.	The	 review	 results	 are	 summarised	 in	Table 
1	 and	how	 these	 results	might	 affect	 practice	 are	 shown	
in	Table 2.
This series of articles facilitated by the Cochrane Musculoskeletal Group (CMSG) aims to place the findings of recent 
Cochrane musculoskeletal reviews in a context immediately relevant to general practitioners. This article considers 
whether the availability of strontium ranelate affects the management of postmenopausal osteoporosis.
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Conclusion
Strontium	 ranelate	 has	 demonstrated	 efficacy	









and	safety	suggests	 that	 it	 could	be	considered	
a	 first	 line	 treatment	 for	 postmenopausal	





in	 this	 population,10	 and	posthoc	 analyses	have	
shown	 decreased	 fracture	 risk	 in	 osteopenic	
postmenopausal	 women	 without	 fractures.14	
However,	more	data	are	 required	 to	confirm	this.	
Further	 research	 is	 also	 needed	 to	 determine	
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